肠脂肪酸结合蛋白对新生儿坏死性小肠结肠炎诊断价值的系统评价

摘要

目的 系统评价肠脂肪酸结合蛋白(i-FABP)对新生儿坏死性小肠结肠炎(NEC)的诊断价值.方法 利用PubMed、EMBASE、万方数据等数据库搜索潜在相关的研究,并对文献进行诊断试验质量评价-2(QUADAS-2)评价.计算纳入研究的合并灵敏度、特异度、阳性似然比(PLR)、阴性似然比(NLR)、诊断比值比(DOR),并绘制SROC曲线用于总体性能的评估.结果 共纳入7项研究.合并的灵敏度、特异度、PLR、NLR、DOR和AUC分别为0.70(95％CI:0.60～0.79)、0.89(95％CI:0.84～0.94)、5.33(95％CI:3.42～8.31)、0.39(95％CI:0.29～0.52)、17.11(95％CI:8.36～34.99)和0.8795. 结论 i-FABP在诊断NEC方面是一种有前途的生物标志物,其特异度和DOR均较高.%Objective To evaluate the application of intestinal fatty-acid-binding protein (i-FABP) in the diagnosis of newborn necrotizing enterocolitis (NEC).Methods A comprehensive literature search was performed from PubMed and EMBASE and Wanfang data to identify relevant studies.QUADAS-2 tool was used to assess the quality of the included studies.The sensitivity,specificity,positive likehood ratio (PLR),negative likehood ratio (NLR),diagnostic odds ratio (DOR),summary receiver operating characteristic curve (SROC) and AUCwere used to evaluate the overall diagnostic performance of i-FABP for NEC.Results Sevenstudies were included.The pooledsensitivity,specificity,PLR,NLR,DOR and AUC of i=FABP for diagnosis of NEC were 0.70 (95％CI:0.60-0.79),0.89 (95％CI:0.84-0.94),5.33 (95％CI:3.42-8.31),0.39(95％CI:0.29-0.52),17.11 (95％CI:8.36-34.99) and 0.8795.Conclusion Plasma i-FABP is a promising biomarker in the diagnosis of NEC with high specificity and DOR.